Evidence map›Paper›PMID 38286960›Full record

ReviewAdvances in therapy2024

Artificial Intelligence in Liver Diseases: Recent Advances.

Feifei Lu, Yao Meng, Xiaoting Song, Xiaotong Li, Zhuang Liu, Chunru Gu, Xiaojie Zheng, Yi Jing, Wei Cai, Kanokwan Pinyopornpanish and 4 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Advances in therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
7.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 7 institutions in 5 countries.

Feifei Lu *College of Medicine and Biological Information Engineering, Northeastern University, Shenyang, China.
Yao Meng *Liver Cirrhosis Study Group, Department of Gastroenterology, General Hospital of Northern Theater Command, No. 83 Wenhua Road, Shenyang, 110840, Liaoning Province, China.
Xiaoting Song *Liver Cirrhosis Study Group, Department of Gastroenterology, General Hospital of Northern Theater Command, No. 83 Wenhua Road, Shenyang, 110840, Liaoning Province, China.
Xiaotong Li *Liver Cirrhosis Study Group, Department of Gastroenterology, General Hospital of Northern Theater Command, No. 83 Wenhua Road, Shenyang, 110840, Liaoning Province, China.
Zhuang Liu *Liver Cirrhosis Study Group, Department of Gastroenterology, General Hospital of Northern Theater Command, No. 83 Wenhua Road, Shenyang, 110840, Liaoning Province, China.
Chunru Gu *Liver Cirrhosis Study Group, Department of Gastroenterology, General Hospital of Northern Theater Command, No. 83 Wenhua Road, Shenyang, 110840, Liaoning Province, China.
Xiaojie Zheng *Liver Cirrhosis Study Group, Department of Gastroenterology, General Hospital of Northern Theater Command, No. 83 Wenhua Road, Shenyang, 110840, Liaoning Province, China.
Yi JingNeusoft Research of Intelligent Healthcare Technology, Co. Ltd., Shenyang, China.
Wei CaiNeusoft Research of Intelligent Healthcare Technology, Co. Ltd., Shenyang, China.
Kanokwan PinyopornpanishDepartment of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
Andrea MancusoMedicina Interna 1, Azienda di Rilievo Nazionale Ad Alta Specializzazione Civico-Di Cristina-Benfratelli, Palermo, Italy. andrea.mancuso329@gmail.com.
Fernando Gomes RomeiroInternal Medicine Department, Botucatu Medical School, São Paulo, Brazil. fgromeiro@gmail.com.
Nahum Méndez-SánchezLiver Research Unit, Medica Sur Clinic and Foundation, National Autonomous University of Mexico, Mexico City, Mexico. nmendez@medicasur.org.mx.
Xingshun QiCollege of Medicine and Biological Information Engineering, Northeastern University, Shenyang, China. xingshunqi@126.com.ORCID 0000-0002-9448-6739
General Hospital of Shenyang Military Region · CNDalian Medical University · CNNeusoft (China) · CNAzienda di Rilievo Nazionale ed Alta Specializzazione · ITChiang Mai University · THHospital Médica Sur · MXMedecell (Brazil) · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Liver diseases cause a significant burden on public health worldwide. In spite of great advances during recent years, there are still many challenges in the diagnosis and treatment of liver diseases. During recent years, artificial intelligence (AI) has been widely used for the diagnosis, risk stratification, and prognostic prediction of various diseases based on clinical datasets and medical images. Accumulative studies have shown its performance for diagnosing patients with nonalcoholic fatty liver disease and liver fibrosis and assessing their severity, and for predicting treatment response and recurrence of hepatocellular carcinoma, outcomes of liver transplantation recipients, and risk of drug-induced liver injury. Herein, we aim to comprehensively summarize the current evidence regarding diagnostic, prognostic, and/or therapeutic role of AI in these common liver diseases.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsNon-alcoholic Fatty Liver DiseaseArtificial IntelligenceHumansLiver CirrhosisArtificial intelligenceCirrhosisDeep learningFibrosisHepaticLiver diseaseMachine learning

Identifiers

PMID38286960
OpenAlexW4391308931

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.